Design and rationale of the EMPEROR trials of empagliflozin 10mg once daily in patients with chronic heart failure with reduced ejection fraction (EMPEROR-Reduced) or preserved ejection fraction (EMPEROR-Preserved)

DIABETIC MEDICINE(2019)

引用 2|浏览3
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要